/

IMMP

Immutep LimitedClosed

3.57−0.10 −2.72%USD

NasdaqGM · as of Oct 13, 16:00 ET · 15m delay

Open

3.60

Prev close

3.67

Day range

3.443.70

52-week range

3.4470.60

Volume

26.99K1.80×

Mkt cap

26.31M

P/E ttm

—

Fwd P/E

-0.69

EPS ttm

-7.30

Div yield

0.00%

Earnings

—

From 52w high

−94.94%

Price Chart

Yahoo Finance · delayed

IMMPOct 13, 2026O 3.60H 3.70L 3.44C 3.57−0.10 (−2.72%)Vol 27.00K

SMA 501.76
SMA 2001.44

1Y change +79.40% since Oct 13, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IMMP Immutep Limited · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −17.74%
1 month: +864.86%
3 months: +730.23%
6 months: +1,051.61%
Year to date: +24.83%
1 year: +79.40%

Valuation & ownership

Market cap: 26.31M
Enterprise value: −41.52M
P/E (ttm): —
Forward P/E: -0.69
PEG ratio: —
Price / book: 0.61
Price / sales (ttm): 1.32
EV / EBITDA: 0.52
EPS (ttm): -7.30
EPS (forward): -5.20
Beta (5y monthly): 2.30
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 7.37M
Float: 6.87M
Short % of float: 1.35%
Short ratio (days): 1.99
Held by insiders: 0.01%
Held by institutions: 1.13%
Avg volume (3m): 14.98K
50-day average: 6.52
200-day average: 20.93
52-week change: +79.40%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 56.6
vs 50-day SMA: +102.63%
vs 200-day SMA: +147.62%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 18.52%
Realised vol (20d, ann.): 1518.1%
From 52-week high: −56.46%
From 52-week low: +1,273.08%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

30.00

+740.34% implied

Low 30.00Median 30.00High 30.00

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 19.93M
Revenue growth (yoy)

DES

About Immutep Limited

Yahoo Finance profile

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Sector: Healthcare
Industry: Biotechnology
Headquarters: Sydney, NSW, Australia
Website: immutep.com

SEAS

Seasonality · IMMP

2012–2026 · monthly returns

Strongest month May +35.27%Weakest month Jun −15.64%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.5	2.6	-87.5	31.4	-4.3	-4.5	-9.5	-2.6	-37.2	-23.2			−93.8%
2025	-3.7	-7.7	-8.8	-2.8	9.9	-12.8	6.1	-7.5	8.7	8.0	7.4	40.9	+31.8%
2024	-9.6	7.8	-0.4	15.5	10.8	-32.6	7.5	21.8	-16.0	-17.6	11.5	6.9	−9.6%
2023	11.4	-16.4	3.1	-2.4	22.6	5.0	2.4	-12.0	0.0	-0.5	5.3	20.6	+37.1%
2022	-16.2	-12.0	13.2	-16.4	29.7	-31.6	11.3	-10.6	-22.8	14.7	34.1	-27.1	−46.6%
2021	-3.2	-11.8	14.6	12.1	46.5	-23.2	-11.6	24.0	-8.7	10.6	-19.9	-4.4	+4.5%
2020	24.6	0.9	-68.0	40.3	21.8	-12.2	24.1	-0.7	30.1	-1.2	15.2	59.4	+75.4%
2019	21.2	-0.4	-1.8	-12.8	2.1	-6.2	-15.4	-7.8	13.4	14.9	-5.9	2.9	−2.7%
2018	15.3	0.6	4.4	-1.6	55.1	-17.9	4.2	5.2	41.8	-18.9	-11.7	-30.6	+17.2%
2017	8.1	15.8	-16.7	2.5	-0.8	-12.9	-26.4	5.7	10.1	18.9	-22.3	-8.2	−32.9%
2016	-16.7	-12.6	14.5	13.7	0.0	-10.2	-4.1	-6.5	2.3	-4.5	0.0	-17.4	−38.4%
2015	25.4	17.9	-24.2	-25.3	307.1	-36.4	-20.7	4.3	5.8	-3.9	-10.7	4.6	+70.1%
2014	10.9	7.4	-16.0	-6.4	40.8	-20.0	-6.0	-1.8	-6.5	2.0	-8.8	-28.0	−39.1%
2013	1.5	4.9	-12.1	-14.6	-17.9	-7.1	44.0	-25.2	-49.8	-9.7	25.5	-14.1	−67.9%
2012					-33.9	-0.9	-21.1	16.6	36.3	-39.1	13.7	-13.8	−51.0%

IMMP

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IMMP

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Immutep Limited

Seasonality · IMMP

Insider Activity · IMMP

Congress Trades · IMMP

Investors Holding IMMP

Investors Holding IMMP

Congress Trades · IMMP

Insider Activity · IMMP

Seasonality · IMMP

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Immutep Limited

Earnings & Dividends

News